Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers
Open Access
- 1 November 2017
- journal article
- case report
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (47) , e8905
Abstract
Angiotensin II receptor blockers (ARBs) are widely used for patients with hypertension, and fimasartan is a recently approved ARBs. Fimasartan can cause headache, dizziness, itching, and coughing. There have been several reports of hepatotoxicity in ARBs. However, there have not yet been published reports of the hepatotoxicity of fimasartan. A 73-year-old man with hypertension experienced liver injury after fimasartan administration. He had a previous history of taking 3 types of ARBs each for more than 2 years before taking fimasartan, and there were no side effects on ARBs except for fimasartan. Other factors that could cause liver injury were excluded in diagnostic tests, and fimasartan was suspected to be the causative agent. Fimasartan was immediately discontinued and the patient was managed with supportive care via hepatotonics. Other factors that could cause liver injury were excluded in diagnostic tests, and fimasartan was suspected to be the causative agent. The liver injury due to fimasartan was confirmed by histology and accidental redosing. We emphasize that liver function should be monitored during fimasartan administration because fimasartan may cause hepatotoxicity in patients who have no side effects with other types of ARBs. And fimasartan-induced liver injury may appear later than other ARBs.Keywords
This publication has 18 references indexed in Scilit:
- Losartan-induced ischemic hepatocellular hepatotoxicity: A case report and literature reviewJournal of Family Medicine and Primary Care, 2014
- Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study)American Journal of Cardiovascular Drugs, 2013
- An Update on Drug-induced Liver InjuryJournal of Clinical and Experimental Hepatology, 2012
- Assessment of the Drug–Drug Interactions Between Fimasartan and Hydrochlorothiazide in Healthy VolunteersJournal of Cardiovascular Pharmacology, 2012
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Fimasartan Following Single and Repeated Oral Administration in the Fasted and Fed States in Healthy SubjectsAmerican Journal of Cardiovascular Drugs, 2011
- Liver enzyme alteration: a guide for cliniciansCanadian Medical Association Journal, 2005
- Drug-Induced HepatotoxicityNew England Journal of Medicine, 2003
- Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicityEuropean Journal of Gastroenterology & Hepatology, 2002
- Drug points: Prolonged cholestasis associated with irbesartanBMJ, 2000
- Losartan-Induced Hepatotoxicity1997